Physician profile
Sheri B Doniger
NPI 1326251190
$10,095.51
in general payments reported to CMS, 2019-2025
7 companies · $2,355 in 2025
The $2,355 reported for 2025 was more than what 98% of General Practice (Dentist) providers received nationally (typical 2025 total: $74.60).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,148 · 2020: $1,235 · 2021: $35.00 · 2023: $1,001 · 2024: $3,321 · 2025: $2,355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $3,000 · Consulting Fee: $1,710 · Travel and Lodging: $1,543 · Gift: $425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $3,000.00 |
| Consulting Fee | $1,710.00 |
| Travel and Lodging | $1,542.66 |
| Gift | $425.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hu-Friedy Mfg. Co., LLC | $3,910.00 | 2019-2025 | |
| Garrison Dental Solutions | $3,425.00 | 2024-2025 | |
| Kuraray America INC. | $1,542.66 | 2023-2024 | |
| Air Techniques, INC. | $1,000.00 | 2020 | |
| Gc America INC. | $99.50 | 2019 | |
| Premier Dental Products Company | $70.00 | 2020-2021 | |
| Zimmer Biomet Holdings, INC. | $48.35 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheri Doniger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.